"The iShares Biotechnology ETF is market-cap weighted, meaning the biggest companies command the largest positions. Gilead Sciences sits at 9.40% of assets, Vertex Pharmaceuticals at 9.10%, and Amgen at 8.92%. The top ten holdings collectively represent nearly 50% of all assets."
"The State Street SPDR S&P Biotech ETF runs equal-weight across roughly 145 holdings, which means that a small company advancing through a Phase 3 trial will get the same portfolio weight as larger firms."
The biotech sector has shown remarkable performance, with the State Street SPDR S&P Biotech ETF returning 40.80% and the iShares Biotechnology ETF gaining 33.95% over the past year. Analysts predict continued recovery into 2026 due to improving fundamentals and regulatory conditions. The iShares ETF is market-cap weighted, concentrating on larger companies, while the SPDR ETF is equal-weighted, allowing smaller firms to have equal influence. This structural difference impacts potential returns based on future biotech developments.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]